When Your Diabetic Cat Might Be a Candidate for an Oral SGLT2 Pill Instead of Insulin Shots
A new feline diabetes diagnosis usually arrives with a syringe kit, a vial of insulin, and a crash course in twice-daily injections that many owners never expected to give. So when a veterinarian mentions an oral option — a once-daily liquid or tablet instead of shots — it can sound like an easy win. Velagliflozin (brand name Senvelgo) and bexagliflozin (brand name Bexacat) are real, FDA-approved medications that work this way, and for a specific type of newly diagnosed cat, they can meaningfully change what daily diabetes care looks like. But the same mechanism that makes them convenient also creates a narrow, unforgiving safety window. Understanding who actually qualifies, and what has to be watched for afterward, matters more than the appeal of skipping injections.
How SGLT2 Inhibitors Lower Blood Sugar Without Insulin
Velagliflozin and bexagliflozin belong to a drug class called sodium-glucose cotransporter-2 (SGLT2) inhibitors. In a healthy cat, the kidneys filter glucose out of the blood and then reabsorb nearly all of it back into circulation, mostly through a transporter called SGLT2 in the early part of the renal proximal tubule. SGLT2 inhibitors block that reabsorption, so instead of glucose being pulled back into the bloodstream, it spills into the urine and leaves the body. Blood glucose drops quickly as a direct result of this urinary loss, not because the drug stimulates the pancreas or improves insulin sensitivity the way some other diabetes medications do.
This is a meaningfully different mechanism from injectable insulin, which replaces the hormone the body isn't producing or using effectively. SGLT2 inhibitors don't replace insulin at all; they lower blood glucose independently of it. That distinction sounds academic, but it's the reason these drugs can work well in one cat and be genuinely dangerous in another. A cat that still produces some of its own insulin can usually keep ketone production in check even while an SGLT2 inhibitor is doing most of the glucose-lowering work. A cat with little or no remaining insulin production cannot, and that's where the risk concentrates.
Both drugs were licensed by the FDA specifically for glycemic control in cats not previously treated with insulin. Bexacat was approved in December 2022 and Senvelgo in 2023, and both labels carry boxed or highlighted warnings about diabetic ketoacidosis risk.
Why "Insulin-Naive" Is a Hard Line, Not a Preference
The single most important eligibility criterion for either drug is that the cat has never been treated with insulin. This isn't a matter of vet preference or a soft recommendation — it's written into both drug labels as a contraindication. Senvelgo's label states plainly that it should not be used in cats previously treated with insulin, currently receiving insulin, or with insulin-dependent diabetes, and that switching an insulin-dependent cat over to the drug is associated with an increased risk of death.
The reasoning traces back to field-trial data. In the velagliflozin licensing study, cats that had previously received insulin developed diabetic ketoacidosis at a rate of about 18%, compared with roughly 5% in insulin-naive cats started on the drug for the first time. That gap exists because prior insulin dependence is itself a signal that a cat's own beta cells have already failed to a meaningful degree — exactly the situation where an SGLT2 inhibitor's glucose-lowering effect can outpace the cat's ability to suppress ketone formation.
A related nuance worth understanding: some cats are diagnosed with diabetes, started on insulin for a few days while diagnostics are finalized, then switched to an SGLT2 inhibitor once a veterinarian is confident in the diagnosis. The peer-reviewed literature on these drugs generally treats a very brief bridging period (on the order of four days or less) differently from cats who have been managed on insulin for weeks or months, but this is a judgment call that belongs to the treating veterinarian, not something an owner should decide independently.
The Screening Workup Before Starting Either Drug
Before an SGLT2 inhibitor is dispensed, a reasonable veterinary workup typically includes bloodwork, a urinalysis, and a baseline ketone measurement, because several coexisting conditions can turn a seemingly straightforward diabetic cat into a poor candidate. Kidney function matters because significant renal impairment can both blunt the drug's effectiveness — since it depends on the kidneys excreting glucose — and increase vulnerability to dehydration. Pancreatitis is a specific concern, since both drug labels advise against starting therapy in cats with clinical or imaging evidence of pancreatic inflammation. Hepatic lipidosis, a serious fatty liver condition that can develop in cats that stop eating, is another reason a cat needs to be assessed rather than simply started on medication because a diagnosis of diabetes is confirmed.
Appetite is one of the simplest but most decisive screening questions. A cat that is eating normally and otherwise clinically well is a fundamentally different candidate than one that has been picky, nauseated, or losing weight in the days before diagnosis. Reduced food intake close to starting therapy is associated with a higher likelihood of complications, which is part of why veterinarians tend to delay SGLT2 inhibitor therapy in any cat that isn't eating reliably.
Baseline ketone testing is not optional in a careful workup. A blood beta-hydroxybutyrate (BHB) level under roughly 1.0 mmol/L is generally considered reassuring, while a level above 2.4 mmol/L is treated as a signal for insulin rather than an oral hypoglycemic, based on data showing that threshold correlates strongly with diagnosable diabetic ketoacidosis.
Euglycemic DKA and Why a Normal Glucose Reading Can Be Misleading
The defining hazard of this drug class is euglycemic diabetic ketoacidosis, often shortened to eDKA. In ordinary diabetic ketoacidosis, a cat is severely hyperglycemic and also ketotic. Euglycemic DKA is different and, in some ways, more dangerous precisely because it doesn't look like a typical crisis: the cat can be building up dangerous levels of ketones and sliding into metabolic acidosis while blood glucose stays normal or only mildly elevated, generally under about 250 mg/dL.
A cat on an SGLT2 inhibitor can be euglycemic despite substantial ketone generation. Checking for ketosis is therefore more important than measuring blood glucose in these patients — a normal glucose reading offers no reassurance about ketoacidosis risk once therapy has started.
The mechanism behind this involves glucagon. Even without exogenous insulin driving glucose down, the drug's glucose-lowering effect can suppress a struggling cat's own residual insulin secretion, which in turn allows glucagon-driven lipolysis and ketone production to escalate unchecked. Because the SGLT2 inhibitor is simultaneously clearing glucose out through the kidneys, the resulting ketosis isn't accompanied by the sky-high blood sugar that owners and even some veterinary staff associate with a diabetic emergency.
The clinical signs to watch for are the same ones that signal any serious metabolic illness in a cat: reduced appetite, vomiting, lethargy, or dehydration. FDA safety communications and both manufacturers' labeling emphasize that any of these signs in a cat on Senvelgo or Bexacat warrants immediate ketone testing, not reassurance from a normal glucose meter reading. In field studies, most cases of DKA or eDKA on these drugs emerged within the first one to two weeks of starting therapy, though the FDA has noted cases can occur later as well.
Blood BHB Testing Versus Urine Ketone Strips
Urine dipstick testing is a familiar, low-cost way to check for ketones, but it measures acetoacetate rather than beta-hydroxybutyrate, and the published literature is fairly direct about its limitations in this specific context. Beta-hydroxybutyrate is the predominant ketone body generated early in ketoacidosis, and urine acetoacetate testing tends to lag behind the actual metabolic picture — a urine strip can still read negative or only trace-positive while blood BHB is already climbing into a concerning range.
For that reason, veterinary guidance for cats on SGLT2 inhibitors leans toward point-of-care blood BHB meters rather than urine strips wherever that's feasible. A blood BHB value above 2.4 mmol/L has been reported as roughly 100% sensitive and around 87% specific for diagnosing DKA in cats, making it a far more decisive number to act on than a urine color change.
A Realistic Monitoring Timeline After Starting Therapy
Peer-reviewed veterinary guidance describes a structured recheck schedule for cats newly started on an SGLT2 inhibitor, built around the fact that most complications surface early. A typical framework includes a check around day 2 to 3 after starting the medication, covering a history review for appetite, vomiting or lethargy, a physical exam, and a blood BHB measurement. Similar rechecks are repeated around day 7 and day 14, with blood glucose or fructosamine added to gauge how well the drug is controlling the diabetes itself. A day 30 recheck typically adds a full reassessment of clinical signs, weight, ketone status, and either blood glucose or fructosamine trends, since fructosamine reflects average glucose control over the preceding several weeks rather than a single moment.
At any point in that schedule, a blood BHB result above 2.4 mmol/L is treated as a trigger to stop the SGLT2 inhibitor and start insulin, while a result in the 1.0 to 2.4 mmol/L range generally prompts a recheck within a few days rather than immediate insulin conversion. Weight loss exceeding roughly 8% from baseline, or a fructosamine level that hasn't improved meaningfully alongside ongoing diabetic signs, are additional reasons a veterinarian may decide the cat needs to transition to insulin rather than continue oral therapy. None of these thresholds are something an owner should interpret and act on alone; they exist to guide a veterinarian's decision about whether to continue, adjust, or abandon oral therapy for that individual cat.
What Happens If a Cat Develops eDKA
If euglycemic DKA is confirmed or strongly suspected, the SGLT2 inhibitor is discontinued immediately, and treatment shifts to the same core approach used for any diabetic ketoacidosis: intravenous fluids, electrolyte correction, and insulin therapy — with the notable addition of dextrose supplementation, since blood glucose is not elevated the way it would be in classic DKA and insulin alone would risk causing dangerous hypoglycemia. This is not a home-management situation under any circumstances; both the FDA and manufacturer safety communications describe eDKA as a life-threatening emergency requiring immediate veterinary or emergency-hospital intervention.
This is also where the appeal of "no more injections" needs to be weighed honestly against reality. Choosing an oral hypoglycemic doesn't mean choosing less monitoring — for the first two to four weeks, it often means more frequent veterinary contact and blood testing than a stable insulin-treated cat would need. The convenience is real for the right candidate, but it comes with a front-loaded vigilance requirement, not a lighter one.
Where Ongoing Endocrine Support Fits Into the Picture
For a cat that has cleared screening and is doing well on an SGLT2 inhibitor, day-to-day management still depends on consistent access to reliable testing supplies and a clear understanding of what each recheck is meant to catch. Owners navigating this process sometimes find it useful to explore feline endocrine solutions to understand what monitoring and supportive care categories exist for diabetic cats, separate from the prescription medication itself, which always requires a veterinarian's oversight and a valid prescription. None of this changes the fact that candidate selection, dosing, and the decision to switch therapies rest entirely with the treating veterinarian — a product category page can inform what questions to ask, but it can't substitute for lab-confirmed screening or an in-person exam.
It's also worth being clear about where this class of drug does not fit. A cat with known kidney disease beyond mild stages, active pancreatitis, hepatic lipidosis, or any degree of prior insulin dependence is not a candidate regardless of how appealing the oral option sounds, and pursuing it anyway risks exactly the euglycemic DKA scenario described above. In those situations, insulin remains the standard of care, and the more relevant conversation with a veterinarian is about injection technique, monitoring tools, and diet — not about switching drug classes.
Frequently Asked Questions
Can a cat that was previously on insulin switch to an oral SGLT2 inhibitor like velagliflozin? No. Both Senvelgo and Bexacat labeling specifically advises against use in cats with any history of insulin treatment, since field-trial data showed a substantially higher rate of diabetic ketoacidosis in previously insulin-treated cats compared with insulin-naive cats started on the drug for the first time.
How do veterinarians test for ketoacidosis if my cat's blood sugar is normal on SGLT2 inhibitors? Blood beta-hydroxybutyrate testing, using a point-of-care meter, is the preferred method, since it detects ketone accumulation directly and doesn't rely on elevated glucose the way a standard DKA picture would; urine dipstick testing is considered less reliable in this specific context because it tends to lag behind the true ketone level.
For any cat showing reduced appetite, vomiting, lethargy, or unusual weakness while on an SGLT2 inhibitor, the appropriate step is contacting a veterinarian for same-day evaluation and ketone testing, not waiting to see if symptoms resolve. Further condition-specific and monitoring resources are available through the HERO Veterinary Knowledge Hub for owners who want to understand what a recheck visit for a cat on oral diabetes therapy typically involves.